These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 24588932)

  • 21. Efficacy of Probiotic Escherichia coli Nissle 1917 in Patients with Irritable Bowel Syndrome: a Double Blind Placebo-controlled Randomized Trial.
    Faghihi AH; Agah S; Masoudi M; Ghafoori SM; Eshraghi A
    Acta Med Indones; 2015 Jul; 47(3):201-8. PubMed ID: 26586385
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cumulative Effects of Psychologic Distress, Visceral Hypersensitivity, and Abnormal Transit on Patient-reported Outcomes in Irritable Bowel Syndrome.
    Simrén M; Törnblom H; Palsson OS; Van Oudenhove L; Whitehead WE; Tack J
    Gastroenterology; 2019 Aug; 157(2):391-402.e2. PubMed ID: 31022401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized double-blind placebo-controlled clinical trial on efficacy and safety of association of simethicone and Bacillus coagulans (Colinox®) in patients with irritable bowel syndrome.
    Urgesi R; Casale C; Pistelli R; Rapaccini GL; de Vitis I
    Eur Rev Med Pharmacol Sci; 2014; 18(9):1344-53. PubMed ID: 24867512
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A double-blind, placebo-controlled study to assess the effect of a probiotic mixture on symptoms and inflammatory markers in women with diarrhea-predominant IBS.
    Hod K; Sperber AD; Ron Y; Boaz M; Dickman R; Berliner S; Halpern Z; Maharshak N; Dekel R
    Neurogastroenterol Motil; 2017 Jul; 29(7):. PubMed ID: 28271623
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of multispecies probiotic supplementation on intestinal microbiota in irritable bowel syndrome.
    Kajander K; Krogius-Kurikka L; Rinttilä T; Karjalainen H; Palva A; Korpela R
    Aliment Pharmacol Ther; 2007 Aug; 26(3):463-73. PubMed ID: 17635381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Symptom severity but not psychopathology predicts visceral hypersensitivity in irritable bowel syndrome.
    van der Veek PP; Van Rood YR; Masclee AA
    Clin Gastroenterol Hepatol; 2008 Mar; 6(3):321-8. PubMed ID: 18258487
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acacia fiber or probiotic supplements to relieve gastrointestinal complaints in patients with constipation-predominant IBS: a 4-week randomized double-blinded placebo-controlled intervention trial.
    JanssenDuijghuijsen L; van den Belt M; Rijnaarts I; Vos P; Guillemet D; Witteman B; de Wit N
    Eur J Nutr; 2024 Aug; 63(5):1983-1994. PubMed ID: 38653808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome.
    Barbara G; Zecchi L; Barbaro R; Cremon C; Bellacosa L; Marcellini M; De Giorgio R; Corinaldesi R; Stanghellini V
    J Clin Gastroenterol; 2012 Oct; 46 Suppl():S52-5. PubMed ID: 22955358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Methods to assess visceral hypersensitivity in irritable bowel syndrome.
    Keszthelyi D; Troost FJ; Masclee AA
    Am J Physiol Gastrointest Liver Physiol; 2012 Jul; 303(2):G141-54. PubMed ID: 22595988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Viscerosomatic facilitation in a subset of IBS patients, an effect mediated by N-methyl-D-aspartate receptors.
    Verne GN; Price DD; Callam CS; Zhang B; Peck J; Zhou Q
    J Pain; 2012 Sep; 13(9):901-9. PubMed ID: 22958874
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life.
    Choi CH; Jo SY; Park HJ; Chang SK; Byeon JS; Myung SJ
    J Clin Gastroenterol; 2011 Sep; 45(8):679-83. PubMed ID: 21301358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term treatment with probiotics in primary care patients with irritable bowel syndrome--a randomised, double-blind, placebo controlled trial.
    Begtrup LM; de Muckadell OB; Kjeldsen J; Christensen RD; Jarbøl DE
    Scand J Gastroenterol; 2013 Oct; 48(10):1127-35. PubMed ID: 23957590
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating.
    Kim HJ; Vazquez Roque MI; Camilleri M; Stephens D; Burton DD; Baxter K; Thomforde G; Zinsmeister AR
    Neurogastroenterol Motil; 2005 Oct; 17(5):687-96. PubMed ID: 16185307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome.
    Whorwell PJ; Altringer L; Morel J; Bond Y; Charbonneau D; O'Mahony L; Kiely B; Shanahan F; Quigley EM
    Am J Gastroenterol; 2006 Jul; 101(7):1581-90. PubMed ID: 16863564
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Poor predictive value of breath hydrogen response for probiotic effects in IBS.
    Yao CK; Barrett JS; Philpott H; Chung AR; van Langenberg D; Garg M; Gibson PR
    J Gastroenterol Hepatol; 2015 Dec; 30(12):1731-9. PubMed ID: 26095068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical trial: the effects of a fermented milk containing three probiotic bacteria in patients with irritable bowel syndrome - a randomized, double-blind, controlled study.
    Simrén M; Ohman L; Olsson J; Svensson U; Ohlson K; Posserud I; Strid H
    Aliment Pharmacol Ther; 2010 Jan; 31(2):218-27. PubMed ID: 19863495
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention.
    Kajander K; Hatakka K; Poussa T; Färkkilä M; Korpela R
    Aliment Pharmacol Ther; 2005 Sep; 22(5):387-94. PubMed ID: 16128676
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of sildenafil on rectal sensitivity and tone in patients with the irritable bowel syndrome.
    Gonçalves de Medeiros MT; de Oliveira RB; dos Santos AA; de Leopoldino DM; Lima MC; Nobre RA; Nobre e Souza MÂ
    Aliment Pharmacol Ther; 2012 Mar; 35(5):577-86. PubMed ID: 22229478
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Probiotic supplement (Lactobacillus acidophilus and bulgaricus) utility in the treatment of irritable bowel syndrome].
    Diaz Ferrer J; Parra V; Bendaño T; Montes P; Solorzano P
    Rev Gastroenterol Peru; 2012; 32(4):387-93. PubMed ID: 23307089
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: a randomized trial.
    Abbas Z; Yakoob J; Jafri W; Ahmad Z; Azam Z; Usman MW; Shamim S; Islam M
    Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):630-9. PubMed ID: 24722560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.